Mariner’s Amphastar Pharmaceuticals AMPH Stock Holding History

Mariner’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,865	Closed	-$239K	–	3136
2023 Q4	$239K	Buy	+3,865	New	+$203K	﹤0.01%	2537

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Mariner's AMPH Position: Q1 2024 in Review

Mariner sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 3,865 shares — an estimated $239K sold.

Mariner first reported a position in AMPH in Q4 2023 and held it in 1 quarter. The position peaked at $239K in Q4 2023. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

Mariner reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Mariner sold 3,865 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $239K.
Mariner first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Mariner's Amphastar Pharmaceuticals position peaked at $239K in Q4 2023.
270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Mariner's 13F filing for Q1 2024, filed 15 May 2024.